

Appl. No. : 09/776,232  
Filed : February 2, 2001

40. (New) The method of Claim 38, wherein the antigen comprises a protein or peptide.

41. (New) The method of Claim 38, wherein the antigen is delivered in a single bolus.

42. (New) The method of Claim 38, wherein the antigen comprises a microorganism.

43. (New) The method of Claim 38, wherein the antigen is delivered in the form of a nucleic acid encoding the antigen.

44. (New) The method of Claim 43, wherein said nucleic acid is plasmid DNA in a formulation comprising about 1-10% ethyl alcohol, 0-1% benzyl alcohol, 0.25-0.5mM EDTA and a citrate-phosphate buffer of pH 7.4-7.8, comprising about 3-50mM citrate and about 90 - 200mM phosphate.

45. (New) A method of inducing a CTL response in a mammal, which method comprises:

delivering a liquid comprising an antigen in a continuous, repeated, or sustained manner directly to the lymphatic system of the mammal at a level sufficient to induce a CTL response in the mammal; and

maintaining the antigen in the mammal's lymphatic system over time sufficient to induce the CTL response.

46. (New) The method of Claim 45, wherein induction of cytotoxic T lymphocytes is obtainable independent of immunopotentiator.

47. (New) The method of Claim 46, wherein the antigen is delivered with a cytokine.

48. (New) The method of Claim 46, wherein the antigen is delivered in the form of a nucleic acid encoding the antigen.

49. (New) The method of Claim 45, wherein the antigen is provided as a component of a microorganism cell, and wherein said microorganism cell comprises a recombinant nucleic acid encoding or promoting expression of said antigen.

50. (New) The method of Claim 45, wherein the CTL response comprises an immunological CTL response.

51. (New) The method of Claim 45, further comprising obtaining a sustained CTL response in the mammal and detecting a CTL response in the mammal.

Appl. No. : 09/776,232  
Filed : February 2, 2001

52. (New) A method of inducing or sustaining a CTL response in a mammal, which method comprises:

delivering an antigen to the mammal at a level sufficient to induce a CTL response in the mammal, wherein the antigen is delivered to the mammal by pumping a physiologically-acceptable composition of the antigen from a device held external to the mammal's body positioned to deliver the antigen-containing composition so that the antigen reaches the mammal's lymph system; and

maintaining the antigen in the mammal's lymphatic system over time sufficient to or maintain the CTL response.

53. (New) The method of Claim 52, wherein said pumping a physiologically-acceptable composition of the antigen comprises pumping from a device held external to the mammal's body through a transmission line.

54. (New) The method of Claim 53, wherein said transmission line comprises a catheter.

55. (New) The method of Claim 54, wherein said catheter is at least 20 mm in length.

56. (New) The method of Claim 52, wherein the antigen is delivered to an area of high lymphatic drainage in the mammal.

57. (New) The method of Claim 52, wherein said maintaining step comprises maintaining the antigen in the mammal's lymphatic system sufficient to maintain the CTL response for a period of time that is substantially co-extensive with a desired duration of the CTL response.

58. (New) The method of Claim 52, wherein delivery of the antigen is directly to the lymphatic system.

59. (New) The method of Claim 52, wherein said delivering comprises delivering the antigen in the form of a vector comprising a nucleic acid encoding the antigen.

#### REMARKS

Claims 1-37 have been cancelled without prejudice. New Claims 38-59 have been added. The new Claims are supported by the specification as originally filed and no new matter is added by any of the new Claims.